D-23129: a potent anticonvulsant in the amygdala kindling model of complex partial seizures

https://doi.org/10.1016/0014-2999(96)00073-8Get rights and content

Abstract

The novel anticonvulsant drug D-23129 (N-(2-amino-4-(4-fluorobenzylamino)-phenyl) carbamic acid ethyl ester) was evaluated in the amygdala kindling model of complex partial seizures in rats. D-23129 exerts potent anticonvulsant activity against both focal and generalized seizures in animal models of epilepsy. After intraperitoneal and oral administration in kindled rats, the substance dose dependently increased the threshold for induction of afterdischarges, exerting significant effects already after 0.01 mg/kg. In higher doses (2.5–5 mg/kg i.p., 10–15 mg/kg p.o.) D-23129 also exerted anticonvulsant effects on other seizure parameters of amygdala-kindled rats, i.e. seizure severity, seizure duration, total duration of behavioural changes and afterdischarge duration. The adverse effects of D-23129 were quantitated in the open field and in the rotarod test, a standard test for motor impairment. D-23129 exerted no adverse effects on behaviour in doses up to 5 mg/kg i.p. and 15 mg/kg p.o. Comparing the adverse effects between kindled and non-kindled rats, no differences were found. The data demonstrate that D-23129 is more potent in the amygdala kindling model of complex partial seizures than in other seizure models. D-23129 is orally active and is devoid of neurotoxic effects in anticonvulsant doses, thus indicating that this compound has potential for antiepileptic therapy.

References (26)

  • RundfeldtC. et al.

    Phenytoin potently increases the threshold for focal seizures in amygdala-kindled rats

    Neuropharmacology

    (1990)
  • YonekawaW.D. et al.

    The effects of anticonvulsant agents on 4-aminopyridine induced epileptiform activity in rat hippocampus in vitro

    Epilepsy Res.

    (1995)
  • LöscherW. et al.

    New drugs for the treatment of epilepsy

    Curr. Opin. Invest. Drugs

    (1993)
  • Cited by (137)

    • K<inf>V</inf>7 potassium channels: A new therapeutic target in smooth muscle disorders

      2014, Drug Discovery Today
      Citation Excerpt :

      Electrophysiological experiments performed on Xenopus oocytes [114] and Chinese hamster ovary (CHO) cells [115,116] overexpressing the KCNQ2/3 heteromultimer showed that retigabine shifted the voltage dependence of channel activation to a more hyperpolarised membrane potential, increased the rate of channel activation and slowed channel deactivation. These results identified the mechanism by which retigabine reduced neuronal excitability in the animal seizure model studies [119–121]. The binding site of retigabine has since been identified as a hydrophobic pocket containing a tryptophan residue (Trp-236 in KV7.2; Trp-265 in KV7.3) in the cytoplasmic part of S5 and S6 to stabilise the channel in the open state [122,123].

    View all citing articles on Scopus
    View full text